Scripps Research Logo

News Release

Calibr and TSRI Executive Matt Tremblay Receives Biocom Catalyst Award

LA JOLLA, CA—September 15, 2017—Matt Tremblay, Ph.D., Chief Operating Officer of the California Institute of Biomedical Research (Calibr) and Vice President of Business Development at The Scripps Research Institute (TSRI), has been named one of Biocom Inc.’s annual Life Science Catalyst Award winners.

The Life Science Catalyst Awards, presented by Biocom in conjunction with the San Diego Venture Group, recognizes 10 accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers making a mark on San Diego’s life science industry before reaching their 40th birthday. 

“Matt’s scientific contributions and business leadership played an important role in establishing Calibr and creating the new model for translational research and innovation represented by the affiliation with TSRI,” said Peter G. Schultz, Ph.D., Chief Executive Officer of both institutes.

Tremblay, now 37, was among the first employees hired by Schultz to help start Calibr in 2012.  He was initially hired to lead a team of biologists in the company’s drug discovery efforts, but quickly became involved in the day-to-day operations and was promoted in rapid succession to his current role as Chief Operating Officer.  Following Calibr’s merger with TSRI in October 2016, Tremblay took on an added role as TSRI’s Vice President for Business Development.

“I’m honored to be recognized with this award and to be part of such a vibrant, innovative life science community here in San Diego,” Tremblay said.

This marks the second year TSRI faculty have been recognized by Biocom for their leadership, innovation and contributions to life sciences.  Last year, TSRI Chemistry Professor Phil Baran received one of the 10 inaugural Life Science Catalyst Awards.

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8118
press@scripps.edu


Matt Tremblay, Ph.D. (High-res image)